{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:31Z","timestamp":1784998951906,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Board certification in surgical oncology improves cancer outcomes, but the impact of medical oncologist certification on systemic therapy outcomes is unknown. We investigated whether the Japanese Society of Medical Oncology (JSMO) board certification of the enrolling physician was associated with treatment quality and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used data from the SCRUM-Japan MONSTAR-SCREEN observational study, a nationwide multicenter genomic screening program enrolling patients from 2019 to 2022. Standard treatment implementation rates were compared across cancer types as a secondary outcome. The primary outcome was overall survival (OS) in patients with metastatic colorectal cancer (mCRC) using Kaplan\u2013Meier analysis and Cox proportional hazards regression with sequential adjustment for clinical and molecular covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 2,184 patients, standard treatment rates were comparable between board-certified and non\u2013board-certified groups (97.0% vs. 96.9%). In 358 patients with mCRC, enrollment by a board-certified physician was associated with longer OS (median, 36.5 vs. 30.7 months; hazard ratio (HR): 0.66, 95% CI 0.50\u20130.87; log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003) even after adjustment for age, sex, tumor sidedness, region, trial participation, molecular targeted therapy, metastatic organ count (HR, 0.73; 95% CI 0.55\u20130.97;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029), and after additional adjustment for RAS and BRAF V600E status (HR, 0.64; 95% CI 0.47\u20130.88;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005). Board-certified physicians used molecular targeted therapy more frequently (89.5% vs. 80.4%;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.036).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>JSMO board certification was independently associated with improved OS in mCRC despite comparable guideline adherence, suggesting that specialist expertise extends beyond treatment selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03069-0","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T11:43:35Z","timestamp":1780746215000},"page":"1431-1440","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of medical oncologist certification on survival outcomes in metastatic colorectal cancer: evidence from the SCRUM-Japan MONSTAR-SCREEN Observational Study"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8646-3094","authenticated-orcid":false,"given":"Kyosuke","family":"Seguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadayoshi","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Nonomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroji","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemichi","family":"Watari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Namikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"3069_CR1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/jnci\/djj019","volume":"98","author":"CC Earle","year":"2006","unstructured":"Earle CC, Schrag D, Neville BA et al (2006) Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. JNCI: J Natl Cancer Inst 98:172\u2013180. https:\/\/doi.org\/10.1093\/jnci\/djj019","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"3069_CR2","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/jso.22154","volume":"106","author":"AS Barbas","year":"2012","unstructured":"Barbas AS, Turley RS, Mantyh CR, Migaly J (2012) Effect of surgeon specialization on long-term survival following colon cancer resection at an NCI\u2010designated cancer center. J Surg Oncol 106:219\u2013223. https:\/\/doi.org\/10.1002\/jso.22154","journal-title":"J Surg Oncol"},{"key":"3069_CR3","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1200\/JCO.2000.18.11.2327","volume":"18","author":"BE Hillner","year":"2000","unstructured":"Hillner BE, Smith TJ, Desch CE (2000) Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. JCO 18:2327\u20132340. https:\/\/doi.org\/10.1200\/JCO.2000.18.11.2327","journal-title":"JCO"},{"key":"3069_CR4","doi-asserted-by":"publisher","first-page":"5480","DOI":"10.1007\/s00464-020-08039-9","volume":"35","author":"O Osagiede","year":"2021","unstructured":"Osagiede O, Haehn DA, Spaulding AC et al (2021) Influence of surgeon specialty and volume on the utilization of minimally invasive surgery and outcomes for colorectal cancer: a retrospective review. Surg Endosc 35:5480\u20135488. https:\/\/doi.org\/10.1007\/s00464-020-08039-9","journal-title":"Surg Endosc"},{"key":"3069_CR5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s10388-024-01080-w","volume":"21","author":"Y Kakeji","year":"2024","unstructured":"Kakeji Y, Yamamoto H, Watanabe M et al (2024) Outcome research on esophagectomy analyzed using nationwide databases in Japan: evidences generated from real-world data. Esophagus 21:411\u2013418. https:\/\/doi.org\/10.1007\/s10388-024-01080-w","journal-title":"Esophagus"},{"key":"3069_CR6","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e23","volume":"29","author":"M Mikami","year":"2018","unstructured":"Mikami M, Shida M, Shibata T et al (2018) Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer. J Gynecol Oncol 29:e23. https:\/\/doi.org\/10.3802\/jgo.2018.29.e23","journal-title":"J Gynecol Oncol"},{"key":"3069_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/GO.21.00314","volume":"8","author":"CV Song","year":"2022","unstructured":"Song CV, Yip C-H, Mohd Taib NA et al (2022) Association between adherence to clinical practice guidelines for adjuvant therapy for breast cancer and survival in a resource-limited setting. JCO Global Oncology e2100314. https:\/\/doi.org\/10.1200\/GO.21.00314","journal-title":"JCO Global Oncology"},{"key":"3069_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2022.100938","volume":"7","author":"LT Tchelebi","year":"2022","unstructured":"Tchelebi LT, Shen B, Wang M et al (2022) Nonadherence to multimodality cancer treatment guidelines in the United States. Adv Radiat Oncol 7:100938. https:\/\/doi.org\/10.1016\/j.adro.2022.100938","journal-title":"Adv Radiat Oncol"},{"key":"3069_CR9","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s12282-020-01206-9","volume":"28","author":"TWF Yen","year":"2021","unstructured":"Yen TWF, Garacci Z, Laud PW et al (2021) Guideline-concordant treatment predicts survival: a National Cancer Database validation study of novel composite locoregional and systemic treatment scores among women with early stage breast cancer. Breast Cancer 28:698\u2013709. https:\/\/doi.org\/10.1007\/s12282-020-01206-9","journal-title":"Breast Cancer"},{"key":"3069_CR10","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.cllc.2017.04.009","volume":"18","author":"HZ Ahmed","year":"2017","unstructured":"Ahmed HZ, Liu Y, O\u2019Connell K et al (2017) Guideline-concordant care improves overall survival for locally advanced non\u2013small-cell lung carcinoma patients: a National Cancer Database analysis. Clin Lung Cancer 18:706\u2013718. https:\/\/doi.org\/10.1016\/j.cllc.2017.04.009","journal-title":"Clin Lung Cancer"},{"key":"3069_CR11","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ygyno.2020.03.016","volume":"157","author":"J Dholakia","year":"2020","unstructured":"Dholakia J, Llamocca E, Quick A et al (2020) Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer. Gynecol Oncol 157:716\u2013722. https:\/\/doi.org\/10.1016\/j.ygyno.2020.03.016","journal-title":"Gynecol Oncol"},{"key":"3069_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/annonc\/mdx738","volume":"29","author":"T Yoshino","year":"2018","unstructured":"Yoshino T, Arnold D, Taniguchi H et al (2018) Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO\u2013ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol 29:44\u201370. https:\/\/doi.org\/10.1093\/annonc\/mdx738","journal-title":"Ann Oncol"},{"key":"3069_CR13","doi-asserted-by":"publisher","first-page":"4425","DOI":"10.1111\/cas.15132","volume":"112","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Fujisawa T, Taniguchi H et al (2021) SCRUM-Japan GI\u2010SCREEN and MONSTAR\u2010SCREEN: path to the realization of biomarker\u2010guided precision oncology in advanced solid tumors. Cancer Sci 112:4425\u20134432. https:\/\/doi.org\/10.1111\/cas.15132","journal-title":"Cancer Sci"},{"key":"3069_CR14","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1038\/s41591-020-1063-5","volume":"26","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Taniguchi H, Ikeda M et al (2020) Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies. Nat Med 26:1859\u20131864. https:\/\/doi.org\/10.1038\/s41591-020-1063-5","journal-title":"Nat Med"},{"key":"3069_CR15","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P (2017) Sensitivity analysis in observational research: introducing the E-value. Ann Intern Med 167:268\u2013274. https:\/\/doi.org\/10.7326\/M16-2607","journal-title":"Ann Intern Med"},{"key":"3069_CR16","doi-asserted-by":"publisher","first-page":"e1609","DOI":"10.1002\/onco.13822","volume":"26","author":"CM Nielson","year":"2021","unstructured":"Nielson CM, Bylsma LC, Fryzek JP et al (2021) Relative dose intensity of chemotherapy and survival in patients with advanced stage solid tumor cancer: a systematic review and meta-analysis. Oncologist 26:e1609\u2013e1618. https:\/\/doi.org\/10.1002\/onco.13822","journal-title":"Oncologist"},{"key":"3069_CR17","doi-asserted-by":"publisher","DOI":"10.1200\/GO-24-00333","author":"CD Bergerot","year":"2024","unstructured":"Bergerot CD, Bergerot PG, Philip EJ et al (2024) Enhancing cancer supportive care: integrating psychosocial support, nutrition, and physical activity using telehealth solutions. JCO Glob Oncol. https:\/\/doi.org\/10.1200\/GO-24-00333","journal-title":"JCO Glob Oncol"},{"key":"3069_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K et al (2023) Panitumumab vs Bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329:1271. https:\/\/doi.org\/10.1001\/jama.2023.4428","journal-title":"JAMA"},{"key":"3069_CR19","first-page":"45","volume":"51","author":"C Ishioka","year":"2024","unstructured":"Ishioka C, Minami H, Ohe Y et al (2024) History of the Japanese Society of Medical Oncology. Gan Kagaku Ryoho 51:45\u201352","journal-title":"Gan Kagaku Ryoho"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03069-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03069-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:44Z","timestamp":1784997344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03069-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3069"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03069-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]},"assertion":[{"value":"20 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T. Hashimoto reports speakers\u2019 bureau from CytoGen, Myriad Genetics, Inc., Miyarisan Pharmaceutical, Inc., Guardant Health Pte Ltd., Takeda Pharmaceutical, and Takata Pharmaceutical; research funding from Takeda Pharmaceutical and TEMPUS, Inc.; and advisory role with Guardant Health Pte Ltd. T. Fujisawa reports honoraria from Amelieff, AstraZeneca, and MSD. T. Shibuki reports personal fees from AstraZeneca and Novartis Pharma. S. Okano reports personal fees from Taiho Pharmaceutical, Eisai, Bayer Yakuhin, Chugai Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, AstraZeneca, MSD, Incyte, and Nihon Servier. C. Morizane reports grants from Eisai, Yakult, Ono, Taiho, J-Pharma, AstraZeneca, Merck, Daiichi Sankyo, and Boehringer Ingelheim; consulting fees from Yakult, MSD, Nihon Servier, Boehringer Ingelheim, and Taiho; and honoraria from Novartis, Yakult, Teijin Pharma, Taiho, Eisai, MSD, and AstraZeneca. N. Nonomura reports lecturer fees from Janssen, Pfizer, Astellas, Takeda, Ono, Novartis, MSD, AstraZeneca, Merck, Bayer, Bristol-Myers Squibb (BMS); and research expenses from J-Oil Mills, Taiho, Nippon Shinyaku, Pfizer, Astellas, and AstraZeneca. H. Iwata reports grant from Chugai, Daiichi Sankyo, and AstraZeneca; consulting fees from Chugai, Daiichi Sankyo, AstraZeneca, MSD, Eli Lilly, Pfizer, and Gilead; and honoraria from Daiichi Sankyo, Chugai, AstraZeneca, Eli Lilly, MSD, Pfizer, Taiho, and Kyowa Kirin. H. Watari reports honoraria from AstraZeneca, Takeda, MSD, and Chugai. K. Namikawa reports honoraria from Ono, Novartis, BMS, MSD, LEO Pharma, and Kaken Pharmaceutical; served as an advisory board for Novartis, MSD, Rakuten Medical, Taiho, and Chugai; and received institutional research grants from HUYABIO International, Takara Bio, MSD, and Toray Industries. Y. Naito reports research funding (to institution) from AbbVie, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Pfizer, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, Chugai Pharmaceutical, Bayer, Takeda Pharmaceutical, Anthos Therapeutics, and Gilead Sciences; consulting fees from AstraZeneca, Eisai, Gilead Sciences, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, Taiho Pharmaceutical, Bayer, Daiichi Sankyo, and Ono Pharmaceutical; and speakers\u2019 bureau from AstraZeneca, Eisai, Ono Pharmaceutical, Guardant Health, Takeda Pharmaceutical, Eli Lilly, Novartis, Pfizer, Chugai Pharmaceutical, PDR Pharma, Nihon Kayaku, Taiho Pharmaceutical, Bristol Myers Squibb, Bayer, Daiichi Sankyo, MSD, and Gilead Sciences. H.Bando reports honoraria from Ono Pharmaceutical, Taiho Pharmaceutical, and Guardant Health. T. Yoshino reports honoraria from Chugai, Takeda, Merck, and Ono; consulting fees from Sumitomo Corp, and Indivumed; and research grants from Bristol-Myers, Chugai, Caris, Daiichi Sankyo, Eisai, Exact Sciences, FALCO Biosystems, Medical & Biological Laboratories, Merus N.V., MSD, Miyarisan, Natera, Nippon Boehringer Ingelheim, Ono, Pfizer, Sysmex, Taiho, and Takeda. The other authors declare no potential conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}